drugset / Trial / NCT00490620

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a proof of principal study to determine whether combination anti-viral therapy with Combivir impacts on hepatic biochemistry in patients with primary biliary cirrhosis

Timeline

Start
2004-01
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 150 mg
Subject Zidovudine Small molecule 300 mg